Clinical trials

#Clinical trial design #Clinical trials #Phase I trial #Phase II trial

This week in drug discovery (8-12 July) 

News round-up for 8-12 July by DDW Senior Digital Content Editor Diana Spencer. Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia… Read More

#News

Woman tests blood glucose level
#Clinical trials #Diabetes #GLP-1 #Phesi #Type 2 diabetes

Increase in diabetes research fuelled by GLP-1s like Ozempic

Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials. The analysis of 66,935 clinical trials reveals that the top five most studied diseases are now breast cancer, solid tumours, stroke, prostate… Read More

#News #Trending News

UK vector
#Brexit #Clinical trials #Drug discovery #Ireland #UK

Biogen’s vision for UK & Ireland  

DDW Editor Reece Armstrong speaks to Kylie Bromley, General Manager and Managing Director of Biogen UK & Ireland, about her career within the life sciences industry and the challenges of navigating a large pharma company within the UK and Ireland.   RA: Could you tell us about your career leading… Read More

#Exclusive Content

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

DDW Highlights podcast expands to include vodcast 

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week has seen… Read More

#News

Gastrointestinal tract
#Cancer #Clinical trials #Drug development #ESMO #Gastrointestinal #Redx Pharma #Wnt inhibition

Redx Pharma reports on zamaporvint cancer treatment trials 

Redx Pharma has announced data from all Phase II clinical trial modules of zamaporvint (RXC004), a potent, selective, orally-active Porcupine inhibitor in development for Wnt-ligand dependent, hard-to-treat gastrointestinal (GI) cancers.   These data, presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress, were from… Read More

#Cancer Research #News

#Biopharma #Clinical trials #Contract Research Organisations (CROs)

Q&A: What attracted Moderna’s Co-founder to the board of Lindus Health?

Earlier this year, Robert S. Langer, Co-founder of Moderna and MIT Professor, made the decision to join the advisory board of Lindus Health, a company labelling itself as an anti-contract research organisation (CRO) and which is dedicated to running faster and more reliable trials for the life sciences industry.  … Read More

#Exclusive Content

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

New DDW Highlights podcast: 1 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It is also available to watch as a vodcast:  This week… Read More

#News

#AI #Biomarkers #Clinical trials #Collaboration #Digital biomarkers #Nucleai #Precision medicine #Proscia

Proscia teams up with Nucleai to improve access to AI biomarkers

Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials.   The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine AI portfolio.    The… Read More

#Business & Investment #News

MHRA
#Cell therapy #Clinical trials #Liver disease #Macrophages #MHRA #Resolution Therapeutics

Green light for engineered macrophage cell therapy study 

Resolution Therapeutics has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I/II EMERALD study for its lead candidate RTX001 for patients with decompensated liver cirrhosis.   EMERALD is an open-label, Phase I/II study which will investigate the safety and… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

This week in drug discovery (24-28 June) 

News round-up for 24-28 June by DDW Senior Digital Content Editor Diana Spencer. This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as… Read More

#News

Clinical trial
#Cannabinoid #Clinical trial design #Clinical trials #Contract Research Organisations (CROs) #Decentralised clinical trials #Medicinal cannabis #Plant-based

New podcast: How to utilise clinical trials in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers three articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Medicinal cannabis: Why more clinical… Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #Phesi

AI digital twins could replace control arm in clinical trials

A new study demonstrates that AI-powered digital twin solutions can potentially replace the standard-of-care (SOC) control arm of a clinical trial. The paper was co-authored by analytics company Phesi and Dr Yi-Bin Chen, Director for the Blood and Marrow Transplant Program at Massachusetts General Hospital. Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Machine learning #PhaseV

ML could facilitate increased adoption of adaptive clinical trials

A new machine learning (ML) software platform has been launched to facilitate wider adoption of advanced and adaptive clinical trials. The latest version of AdaptV includes an advanced mode to support more in-depth modifications of relevant algorithmic and statistical parameters that go into trial design, accounting… Read More

#News

#Cancer research #Clinical trials #Funding #iOnctura #Non-small cell lung cancer (NSCLC) #Seed funding

iOnctura announces €80m to progress pipeline  

iOnctura has closed an €80 million Series B financing to continue developing a portfolio of precision oral small molecules that target cancers in novel ways.   The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council… Read More

#Business & Investment #Cancer Research #News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Conference speaker
#ASCO #Clinical trials #Drug discovery #Events #Oncology #Preclinical investigations

ASCO 2024 research highlights

As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. RP1 and RP2 for melanoma… Read More

#Cancer Research #News #Trending News